Million-Dollar CAR-T Therapies Fail to Make National Reimbursement Negotiation List Again

On the 17th, the annual medical insurance negotiation officially began. It was reported that Fosun Kite's CAR-T cell therapy Axicabtagene Ciloleucel Injection (trade name: Yikaida) failed to make it onto the list for this year’s medical insurance negotiation. There are also reports indicating that another CAR-T cell therapy, JW Therapeutics' Relmacabtagene Autoleucel Injection (trade name: Bynoe), also did not enter the medical insurance negotiation list. When contacted for confirmation, JW Therapeutics stated that “it is not convenient to disclose at this time.” To date, four CAR-T cell therapies have been approved for marketing in China, with all of these products’ indications limited to the field of hematological tumors. (First Financial)Original Link